Aeterna Zentaris Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gilles R. Gagnon
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 315 Sigma Drive Summerville SC United States of America 29486
- IPO Date
- May 10, 2000
- CIK
- 0001113423
- Website
- zentaris.com
- Similar Companies
- Business
- COSCIENS Biopharma Inc. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc. Aeterna Zentaris Inc., operates as a specialty biopharmaceutical company that develops and commercializes a diversified portfolio of pharmaceutical products, diagnostic tests, and active ingredients derived from renewable plant resources for the healthcare, cosmetics, nutraceutical, and pharmaceutical industries; its core offerings include macimorelin (marketed as Macrilen in the U.S. and Ghryvelin in Europe), the first and only FDA- and European Commission-approved oral diagnostic test for adult growth hormone deficiency, alongside proprietary natural extracts such as oat beta glucan for skin moisture barrier replenishment, wound healing, cholesterol reduction, blood sugar control, and gut health; oat avenanthramides in liquid and superfine powder forms to soothe itchy skin, reduce redness and inflammation linked to exercise, heart disease, diabetes, and arthritis; and oat oil rich in antioxidants, vitamin E, essential fatty acids, and emollients to enhance skin barrier function, hydration, and softness for cosmetics and hair products. The company targets endocrinology and oncology therapeutic areas, as well as cosmeceutical and nutraceutical markets served by leading skincare brands like Aveeno and Burt’s Bees, with global operations spanning North America, Europe, and production facilities leveraging green extraction technologies from plant sources. Founded in 1990 and headquartered in Charleston, South Carolina, with additional offices in Québec City, Canada, and Frankfurt, Germany, COSCIENS maintains listings on NASDAQ and TSX. In recent developments, the company completed an all-stock merger of equals with Ceapro Inc. in June 2024, integrating Ceapro’s plant-based extraction capabilities to diversify revenue streams and support pipeline advancement; it changed its name from Aeterna Zentaris Inc. to COSCIENS Biopharma Inc. effective August 6, 2024, with trading symbol shifting from AEZS to CSCI on both exchanges starting August 9, 2024; and continues to pursue out-licensing and partnerships for macimorelin commercialization, including prior deals in European markets.
Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.
Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
Shareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to Shareholders
Aeterna Zentaris and Ceapro Complete Merger Transaction
Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
Aeterna Zentaris Reports First Quarter 2024 Financial Results
Aeterna Zentaris Announces Effective Date of Share Consolidation
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
AEZS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aeterna Zentaris Inc. Is Fair to Shareholders
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
Aeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates
Aeterna Zentaris Reports Second Quarter 2023 Financial Results
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update